Impact of Filtration on Autologous Serum Eye Drops
Optimization of Autologous Serum Eye Drops: Study of Filtration on Active Molecule Concentration in Patients With Dry Eye Disease (IFilCoSA)
University Hospital, Limoges
10 participants
Apr 13, 2026
INTERVENTIONAL
Conditions
Summary
Dry eye disease accounts for nearly 25% of ophthalmology consultations, making it a commonly encountered condition. When conventional treatments fail autologous serum in the form of eye drops, have been proposed as a therapeutic option. With the aim of standardizing the preparation of autologous serum eye drops in France, the main objective is to describe the absolute and relative differences (before and after filtration) in the concentrations of active molecules in the autologous serum of patients suffering from severe dry eye disease.
Eligibility
Inclusion Criteria5
- adult patients
- patients covered by health insurance
- patients managed by the Ophtalmology Department of the University Hospital of Limoges
- patients diagnosed with dry eyes syndrome, who have not responded to conventionnal treatments
- free, informed, written and signed consent
Exclusion Criteria4
- person incapable of consent
- legal guardianship or wardship
- patient who does not wish to know the results of serological tests
- \- a positive serology for at least of of the following agents (HIV, HCV, HBV or syphilis)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Dosage of active molecules of autologous serum: TGF β, IGF 1, EGF, fibronectin and vitamin A
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07407101